Lacosamide Hikma Farmacêutica (Portugal)

Lacosamide, the active ingredient in Lacosamide Hikma Farmacêutica, is an anticonvulsant presented as an injectable solution for intravenous use. It treats partial‑onset seizures and epilepsy in patients requiring seizure control.

GNH USA supplies Lacosamide Hikma Farmacêutica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anticonvulsant used in the management of seizure disorders.

- Partial‑onset seizures: reduces seizure frequency as adjunctive therapy. - Focal epilepsy: improves overall seizure control when added to existing regimens. - Adjunctive therapy for epilepsy: enhances seizure management in patients not fully controlled by other antiepileptics.

Side effects may occur with lacosamide therapy.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: feeling of stomach upset or urge to vomit. - Headache: mild to moderate cranial pain. - Fatigue: unusual tiredness or lack of energy. - Blurred vision: temporary visual disturbances. - Diplopia: double vision episodes.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm, including atrioventricular block. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal thoughts: emergence of depressive ideation. - Respiratory depression: significant breathing difficulty.

Precautions should be considered before initiating lacosamide therapy.

- Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Cardiac conduction disorders: evaluate ECG for PR interval prolongation. - Concomitant antiepileptics: monitor for additive CNS effects. - Pregnancy and breastfeeding: safety not established; weigh risks and benefits. - Store at room temperature: keep in original packaging, protect from moisture and light.

Drug interactions may affect lacosamide’s efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce lacosamide plasma levels. - Other sodium‑channel blockers (e.g., phenytoin, lamotrigine): increase risk of CNS depression. - QT‑prolonging agents (e.g., quinidine): heighten risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Valproate: may require therapeutic drug monitoring. - Alcohol: can enhance dizziness and sedation. - Antihypertensives: monitor blood pressure for additive effects.